| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LTBP2 |
| Uniprot No | Q14767 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LTBP2重组蛋白的参考文献示例(部分内容基于模拟研究场景，供参考)：
---
1. **标题**: *"Recombinant LTBP2 expression and its role in extracellular matrix remodeling"*
**作者**: Hirani R, et al.
**摘要**: 本研究利用哺乳动物细胞系统成功表达了重组LTBP2蛋白，并证实其通过调控细胞外基质(ECM)的组装影响组织纤维化进程。实验表明LTBP2与纤维连接蛋白(Fibronectin)的相互作用可能参与肺纤维化病理机制。
2. **标题**: *"Structural and functional characterization of LTBP2 in TGF-β activation"*
**作者**: Todorović V, et al.
**摘要**: 通过重组LTBP2蛋白的晶体结构解析，揭示了其与TGF-β前体复合物的结合模式，证明LTBP2在调控TGF-β信号释放中的关键作用，为靶向纤维化疾病的治疗策略提供依据。
3. **标题**: *"LTBP2 as a biomarker for Marfan syndrome: Development of a recombinant protein-based assay"*
**作者**: Nataatmadja M, et al.
**摘要**: 研究利用重组LTBP2蛋白开发了一种新型ELISA检测方法，发现其在马凡综合征患者血清中显著升高，提示其作为疾病诊断和预后评估的潜在生物标志物。
4. **标题**: *"Recombinant LTBP2 modulates angiogenesis through integrin-mediated signaling"*
**作者**: Kantola AK, et al.
**摘要**: 实验证明重组LTBP2蛋白通过整合素αVβ3依赖性途径抑制血管内皮细胞迁移和血管生成，为抗肿瘤血管生成治疗提供了新的分子靶点。
---
**注**：以上文献为示例性内容，实际研究中请通过PubMed、Web of Science等数据库检索真实发表的论文。
Latent Transforming Growth Factor-beta Binding Protein 2 (LTBP2) is a multifunctional extracellular matrix (ECM) glycoprotein belonging to the fibrillin/LTBP superfamily. It plays a critical role in regulating the bioavailability and activity of Transforming Growth Factor-beta (TGF-β), a key signaling molecule involved in cell proliferation, differentiation, and tissue homeostasis. Unlike other LTBPs, LTBP2 does not directly bind TGF-β in its latent complex but contributes to ECM organization by interacting with fibrillin-1. fibronectin, and integrins. This interaction stabilizes ECM architecture and influences cell-matrix communication.
Recombinant LTBP2 protein is produced using biotechnological methods, such as expression in mammalian or insect cell systems, to ensure proper post-translational modifications. Its recombinant form enables researchers to study LTBP2's structural domains, including cysteine-rich regions and calcium-binding EGF-like motifs, which mediate its ECM-binding and cell-signaling functions. Studies highlight LTBP2's involvement in developmental processes, tissue repair, and pathologies such as fibrosis, cancer metastasis, and cardiovascular disorders. For example, LTBP2 overexpression has been linked to tumor progression and abnormal ECM remodeling in glaucoma.
Research on recombinant LTBP2 also explores its potential as a biomarker or therapeutic target. Its dysregulation in diseases underscores the need to dissect its molecular interactions and signaling pathways. By leveraging recombinant LTBP2. scientists aim to develop targeted therapies to modulate TGF-β signaling or restore ECM integrity, offering insights into treating conditions driven by aberrant matrix dynamics.
×
